A woman in her mid to late 60s who winters down south and summers in Massachusetts. She saw me initially one year ago and wished to look better in a natural way but without surgery. Much of the aging process is volume loss, and when we replace it carefully and leave things a little under-corrected patients look natural but more “rested” If you need 2 coats of paint on your house, you can’t start with one can. She has significant volume depletion and benefits from multiple syringes to replace the deficit in stages.
The first treatment diagram shows our first treatment with 3 syringes of resilient hyaluronic acid “3” ( RHA 3) and 3 syringes of RHA 4. The RHA’s have the benefit of other Non-Animal Stabilized Hyaluronic Acid (NASHA) fillers such as the Restylane family and the Juvederm family but are a little more Resiliient- it is flexible and move well with the face, avoiding unusual bunching or deformities with animation. The RHA 4 is the thickest and is better for deep filling. The RHA 3 is a little less thick and is better closer to the surface. She was on her way back to Florida and didn’t have a chance to come back until this summer.
With the second treatment this summer, I placed 5 syringes of RHA 4 to augment her chin and jawline. This is not a facelift but when enough volume is used can improve the jawline nicely and lasts for nearly 2 years. I also place short-acting neurotoxins to the corrugator (the 11’s”) muscles and the long-acting neurotoxin DAXXIFY to the lateral canthal lines and procerus muscle. We were fortunate to be one of the first 300 preview practices in the United States with Daxxify and were some of the first to use it, starting last December. What we found is that as documented in the studies it lasts 2 months longer than the shorter-acting neurotoxins such as Botox, Dysport, Xeomin, or Juveau. The effects seem stronger, and it is especially great at the lateral canthal lines, where it lasts closer to 5 months with the maximum we typically saw with Botox there being 3 months. It is also stronger in the “11’s”. But in patients that have an early but compensated drooping of the eyelid- in her case, she has this on her left eyelid- the Daxxify is so strong that it seemed to enhance this and make it more noticeable. The eyelid ptosis rate with Daxxify is the same as Botox in the studies, 1-2 % so this is not true ptosis or drooping but does make it more noticeable. So in someone like our patient here I use a hybrid or “blended” approach with Botox or another short-acting neurotoxin to the corrugator muscles and Daxxify elsewhere.
Her afterview shows a nice improvement in side/oblique and frontal views. She is back to her winter home and we plan to see her for an update when she is back in Massachusetts next summer.
Cosmetic & Plastic Surgery Specialist
"I treat my patients like I would treat
- Jonathan D. Hall, MD, FACSmembers of my own family."
Schedule Consultation